Axiom Discovery Inc. is a discovery-informatics company dedicated to
developing and applying in-silico technologies to the drug discovery
process. The company was founded in 2002 by Dr. Kam Chana.
We have developed a suite
of software to enable in-silico drug discovery on the PC platform. Our
molecular modeling technologies provide a complete solution from binding
site identification and receptor modeling to lead discovery.
Our approach of de novo
lead identification reduces the need for high throughput screening of
hundreds of thousands of compounds. These focused libraries of ligands
are optimized to reduce negative side effects such as toxicity that
increase costs of in-vitro discovery. A typical drug development
project costs up to $800 million over a 8 to 12 year period. Use of in-silico
methods offer the potential of reducing costs by up to $200 million and
time by 3 years.
Axiom Discovery works in
close collaboration with industry leaders in computational chemistry,
and data mining and data visualization technology to provide unique and
cost effective out of the box solutions. Our in-silico discovery
framework also allows for customization of key elements of the discovery
process to provide tailored solutions in a robust and feature rich
Kam Chana, Ph.D.
President and Chief Executive Officer
Dr. Chana is the founder, president and
chief executive officer of Axiom Discovery Inc. He has over 10 years of
scientific software experience. He has worked in a variety of fields
with an underlying theme of scientific visualization, simulation and
computation including 3D medical imaging and virtual reality
applications, real time computer simulation, modeling and visualization
of neural networks and processes, and computational chemistry and
physics. Prior to forming Axiom he was at CambridgeSoft as Director for
the Chem3D molecular modeling software suite. His contributions to this
product significantly enhanced its visualization, computation and ease
of use capabilities. He was Head of Visualization and Simulation at Vox-L,
Inc. where he developed software products for medical visualization and
research. Dr. Chana has experience at all levels of product development,
from design, implementation and release, quality assurance,
documentation, to marketing and management. Dr. Chana holds a BSc.(Hons.)
in Physics and Computer Science from Nottingham Trent University, UK and
a Ph.D. in Theoretical and Computational Physics from Loughborough
Vice President, BioIT Group, Fujitsu America, Inc.
Dr. McManus has over 16 years of scientific software and business
experience. Dr. McManus served as Executive Vice President at AnVil
Informatics where he helped raise capital and market awareness of the
company. He was also co-founder of AnVil Informatics. He served as
Vice President of Marketing and Business Development at CambridgeSoft
Corporation for five years. During his tenure at CambridgeSoft, Dr.
McManus was instrumental in creating the company's extensive penetration
into the pharmaceutical and biotech markets. He drove the creation of
the strongest desktop chemistry software brand in the world with a
product user base that grew from 20,000 to 250,000 users.
John J. Hallinan,
Chief Financial Officer, Signet Laboratories, Inc
John Hallinan has 20 years experience in providing financial and
operational management to technology firms. Prior to joining Signet
Laboratories, he was CFO at AnVil Informatics and Animation Technologies
of Boston, Mass. He also served nine years at CambridgeSoft
Corporation, holding the positions of VP Finance, CFO, and Controller.
He provided financial direction that grew the company to $10 million
annual revenues through cash flow.
President & CEO, Nicolino Associates, Inc.
Carl Nicolino is President of Nicolino Associates, Inc., a management
consultant firm specializing in business development and deal-making for
biotechnology and pharmaceutical company clients since 1987. Mr.
Nicolino has been retained by nearly 100 clients including pharma
(Warner-Lambert, Parke-Davis, BASF, Astra, Schering-Plough, Bausch &
Lomb) and biotech (Sepracor, Theratechnologies, Labopharm, AnVil,
Unigene, RTP Pharma, Organogenesis, Prometic Life Sciences, CentraPharm,
Biomat, Red Rock Labs., PolyGenyx, Biostream, Pan-Pacific, Enamelon,
etc. Many of these engagements were long term including over 10 years
with Warner-Lambert and over 5 years with Sepracor, Theratechnologies,
Labopharm and Unigene because of outstanding results delivered.
Previously Mr. Nicolino was at BBN as a VP of Marketing and at
Becton-Dickinson in a number of management, sales, marketing and R&D
capacities. He has a MBA from Wharton and a BS in Physics (minors in
Math and Chemistry) from Brooklyn College.
Richard Morris, Ph.D.
Chief Executive Officer,
Richard Morris is the
Chief Executive Officer of PharmaSeq. He has over 25 years experience in
scientific instrumentation and biotechnology. Dr. Morris began his
career at Dionex Corporation, where he rose to Vice President of
International Operations. He then became Vice President of Worldwide
Sales at Molecular Dynamics, where he managed sales and service
operations. Subsequently, Dr. Morris was the President of Sigma-Aldrich
Research, where he directed worldwide sales of catalog research products
and the supervision of sales and marketing services. His most recent
position before joining PharmaSeq was at CambridgeSoft Corporation,
where he was President of Enterprise Products and Chief Marketing